RNL Replay: SpA

Be sure to sign up for this week's TNR: Spondyloarthritis Spectrum on Tuesday April 23rd at 6:30pm EST. 

What is the difference between non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS)?

How does the clinical response to TNF inhibitors in nr-axSpA compare to AS?

Which imaging technique is preferred for detecting enthesitis due to its ability to assess both soft-tissue components and new bone formation?

What is the first-line treatment for patients with active AxSpA, according to the ASAS EULAR AxSpA Recommendations?

According to the 2023 ASAS-EULAR Recommendations, which treatment approach should be considered in patients with persistently high disease activity, despite conventional treatments?

According to the 2023 ASAS-EULAR Recommendations, IL-17i are contraindicated in patients with active Inflammatory Bowel Disease (IBD).

IL-23 inhibitors are highly effective in the treatment of AxSpA.

Which advanced therapy is superior in treating enthesitis in PsA/SpA?

I am a::

×